The three major agglomeration trends in the development of China's biopharmaceutical industry will further strengthen
The "12th Five-Year Plan" for bio-industries will be released in May of this year. Industry insiders stated that the state emphasizes the development of a modern bio-industry focused on bio-medicine and so on, which will inject a boost to the bio-pharmaceutical industry in China. Biopharmaceutical products will benefit from expansion, but there is also a need to guard against the concept of "storytelling" in investment. It is reported that, unlike the "Twelfth Five-Year Plan" for bio-medicine in the "Twelfth Five-Year Plan for Biotechnology Development" issued by the Ministry of Science and Technology in November last year, the National Development and Reform Commission took the lead in drafting the above plan, focusing on Industrial layout and industrial chain, rather than focus on industrial development data. According to Guo Fanli, a research fellow in the pharmaceutical industry of China Investment Advisors, the prospects for the development of China's biopharmaceutical industry will be broad in the future due to the expansion of new medical reforms and the country’s tilting policies and economics. On the one hand, the basis and time for the development of the biopharmaceutical industry in various parts of the country are different. Therefore, the industry distribution has very distinctive characteristics. From the current point of view, the Yangtze River Delta, Bohai Rim, and the Pearl River Delta, the Northeast, etc. The rapid development of the regional industrial spatial pattern. On the other hand, hot spots for the development of the domestic biopharmaceutical industry continue to emerge. This is mainly in areas with relatively high levels of economic development. For example, in the Pearl River Delta region, its pharmaceutical circulation system is well developed and is adjacent to Hong Kong and Macao. It has strong external radiation capabilities and private capital is relatively active. Some cities such as Shenzhen, Guangzhou, Foshan, Dongguan relying on raw materials and other resource advantages, or have a number of dragon skull medicine companies and strength parks, will become an important source of regional biomedical development. The market predicts that during the 12th Five-Year Plan period, the three major agglomeration trends in the development of China's biopharmaceutical industry will be further strengthened, that is, gathering in parks, gathering in economically developed areas, and gathering in specialized intellectual-intensive areas. In particular, the R&D and clinical links will be further concentrated in provinces and cities where scientific research institutes in the Yangtze River Delta, Pearl River Delta and other coastal areas are concentrated and have strong innovation capabilities. However, for the development of biopharmaceuticals, Jun Tang, vice president of Capital Investment, interviewed by reporters on the 24th in the "China Medical Economic Strategy Summit" interview, said that the pharmaceutical industry is subject to a very large policy related industries, although the national policy to biological The inclination of medicine will help the development of biopharmaceuticals, but due to factors such as costs and prices in the industrial chain, it is necessary to pay attention to the risk of market fluctuations. Hong Tan also specifically proposed that considering the high input, high risk, and long research and development cycle of bio-pharmaceuticals, investors should not simply become obsessed with a new type of drug advocated by the market when they choose bio-pharmaceutical targets (not listed at home and abroad). Drugs) "Story." Custom Size Steel Sectional Garage Door Lifting Commercial Use sectional garage door lifting door overhead door SHENZHEN HONGFA AUTOMATIC DOOR CO., LTD , https://www.hongfarrd.com